Savara (SVRA) Total Current Liabilities (2010 - 2026)
Savara's (SVRA) quarterly Total Current Liabilities came in at $15.5 million in Q1 2026, up 30.6% year-on-year from $11.9 million in Q1 2025, and down 23.81% on a QoQ basis from $20.4 million in Q4 2025.
Savara (SVRA) Total Current Liabilities (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Total Current Liabilities data on file, last reported at $15.5 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 30.6% year-over-year to $15.5 million in Q1 2026; TTM through Mar 2026 was $15.5 million, a 30.6% increase from a year earlier, with the FY2025 full-year figure at $20.4 million, up 38.52% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $15.5 million, down from $20.4 million in the prior quarter.
- Over the last five years, Total Current Liabilities for SVRA reached as high as $20.4 million in Q4 2025 and fell as low as $3.7 million in Q2 2022.
- Historically, Total Current Liabilities has averaged $11.1 million across 5 years, with a median of $11.3 million in 2024.
- Across the five-year window, Total Current Liabilities surged 126.49% in 2022 and tumbled 69.85% in 2023, its largest moves.
- Year by year, Total Current Liabilities stood at $5.9 million in 2022, then jumped by 80.62% to $10.6 million in 2023, then jumped by 38.94% to $14.7 million in 2024, then soared by 38.52% to $20.4 million in 2025, then slipped by 23.81% to $15.5 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $15.5 million in Q1 2026, $20.4 million in Q4 2025, and $16.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | 15.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.54 Mn |
| Dec 31, 2025 | 20.40 Mn |
| Sep 30, 2025 | 16.76 Mn |
| Jun 30, 2025 | 13.63 Mn |
| Mar 31, 2025 | 11.90 Mn |
| Dec 31, 2024 | 14.72 Mn |
| Sep 30, 2024 | 12.79 Mn |
| Jun 30, 2024 | 11.29 Mn |
| Mar 31, 2024 | 9.81 Mn |
| Dec 31, 2023 | 10.60 Mn |
| Sep 30, 2023 | 8.96 Mn |
| Jun 30, 2023 | 5.89 Mn |
| Mar 31, 2023 | 4.92 Mn |
| Dec 31, 2022 | 5.87 Mn |
| Sep 30, 2022 | 5.16 Mn |
| Jun 30, 2022 | 3.71 Mn |
| Mar 31, 2022 | 16.32 Mn |
| Dec 31, 2021 | 14.66 Mn |
| Sep 30, 2021 | 10.66 Mn |
| Jun 30, 2021 | 5.64 Mn |